TOR: The ancient link between cancer and ageing?: Could ageing and cancer be unified by TOR via the 'compromise' struck between soma and germline at the dawn of multicellular life?

BioEssays

Volumn 34, Issue 6, 2012, Pages 443-444

  Moore, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

AGING; CAENORHABDITIS ELEGANS; EDITORIAL; EPITHELIAL MESENCHYMAL TRANSITION; GERM LINE GENE THERAPY; HUMAN; LIPID METABOLISM; NEMATODE; NEOPLASM; NONHUMAN; PLEIOTROPY; PROGENY; SIGNAL TRANSDUCTION; YEAST;

AGING; ANIMALS; CAENORHABDITIS ELEGANS; LIPIDS; METABOLIC SYNDROME X;

EID: 84862080017     PISSN: 02659247     EISSN: 15211878     Source Type: Journal    
DOI: 10.1002/bies.201290022     Document Type: Editorial

References (11)

1. Ackerman D, Gems D. 2012. The mystery of C. elegans aging: an emerging role for fat. BioEssays 34: 466-71.
2. Kaeberlein M, Kapahi P. 2009. Aging is RSKy business. Science 326: 55-6.
3. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. 2009. The TOR pathway comes of age. Biochim Biophys Acta 1790: 1067-74.
4. Kaeberlein M. 2010. Resveratrol and rapamycin: are they anti-aging drugs? BioEssays 32: 96-9.
5. Moore A. 2012. Cancer: escape route from a "doomed" host? BioEssays 34: 2.
6. Blagosklonny MV. 2010. Revisiting the antagonistic pleiotropy theory of aging - TOR driven program and quasi program. Cell Cycle 9: 3151-6.
7. Tang B, Vu M, Booker T, Santner SJ, et al. 2003. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-24.
8. Wendt MK, Tian MZ, Schiemann WP. 2012. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res 347: 85-101.
9. Grandori C, Cowley SM, James LP, Eisenman RN. 2000. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-99.
10. Larsson LG, Henriksson MA. 2010. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 316: 1429-37.
11. Vincent M. 2012. Cancer: A de-repression of a default survival program common to all cells? BioEssays 34: 72-82.